CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial
Dyslipidaemia is a well-known risk factor for coronary artery disease (CAD), and reducing lipid levels is essential for secondary prevention in management of these high-risk individuals. Dyslipidaemia is common also in patients with obstructive sleep apnea (OSA). Continuous positive airway pressure...
Main Authors: | Yeliz Celik, Baran Balcan, Yüksel Peker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/1/273 |
Similar Items
-
Effect of Obstructive Sleep Apnea and CPAP Treatment on Cardiovascular Outcomes in Acute Coronary Syndrome in the RICCADSA Trial
by: Yüksel Peker, et al.
Published: (2020-12-01) -
Postoperative Atrial Fibrillation in Adults with Obstructive Sleep Apnea Undergoing Coronary Artery Bypass Grafting in the RICCADSA Cohort
by: Yüksel Peker, et al.
Published: (2022-04-01) -
REM-Predominant Obstructive Sleep Apnea in Patients with Coronary Artery Disease
by: Baran Balcan, et al.
Published: (2022-07-01) -
The Effect of Continuous Positive Airway Pressure Therapy on Obstructive Sleep Apnea-Related Hypertension
by: Ronni Baran, et al.
Published: (2021-02-01) -
Effect of withdrawing long-term CPAP therapy on the course of obstructive sleep apnea
by: M. V. Agaltsov, et al.
Published: (2021-07-01)